LA-MeO
LA-MeO, also known as lysergic acid ethyl-2-methoxyethylamide or as N-ethyl-N-lysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide. It is the O-methyl ether derivative of the LSD metabolite lysergic acid ethyl-2-hydroxyethylamide.
The drug shows high affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. It acts as a potent partial agonist of the serotonin 5-HT2A receptor similarly to LSD, with an of 30.3nM and an of 29.6%.
LA-MeO was first described in the scientific literature by Jason C. Parrish of the lab of David E. Nichols at Purdue University by 2007.